UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011814
Receipt number R000013803
Scientific Title Development of non-invasive method for the detection of mutated circulating nuclear acid
Date of disclosure of the study information 2013/09/19
Last modified on 2021/03/25 11:37:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Development of non-invasive method for the detection of mutated circulating nuclear acid

Acronym

Development of non-invasive method for the detection of mutated circulating nuclear acid

Scientific Title

Development of non-invasive method for the detection of mutated circulating nuclear acid

Scientific Title:Acronym

Development of non-invasive method for the detection of mutated circulating nuclear acid

Region

Japan


Condition

Condition

Pancreatic cancer
Colon cancer
Hepatocellar carcinoma
Gastric cancer
Bile duct cancer
Inflammatory bowel disease
(Ulcerative colitis, Crohn)
Intraductal papillary mucinous neoplasm
Autoimmune disease
Hepatic/ digestive tract disorder

Classification by specialty

Gastroenterology Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The objectives of this study are: to measure the concentrations of circulating DNA in blood and body fluids before and after examination in patients with hepatic/ digestive tract disorder and confirm their usefulness as predictors of diagnosis; and to investigate correlations between the rare mutation (and gene amplification etc) and the subsequent treatment effect.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Detection rate of rare mutation

Key secondary outcomes

Overall survival (OS)
Progression free survival (PFS)
Tumor marker assessment


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients for whom examination for hepatic /digestive tract disorder is selected in clinical practice
2)Patients who have provided written informed consent for participation in this study

Key exclusion criteria

Patients judged by the principal investigator or subinvestigator to be unsuitable for participation for any other reason (to ensure the safe conduct of this study)

Target sample size

300


Research contact person

Name of lead principal investigator

1st name HIDEAKI
Middle name
Last name KINUGASA

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Division name

GASTROENTEROLOGY

Zip code

700-8558

Address

2-5-1 SHIKATA-CHO KITA-KU OKAYAMA CITY

TEL

086-235-7218

Email

gyacy14@gmail.com


Public contact

Name of contact person

1st name HIDEAKI
Middle name
Last name KINUGASA

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Division name

GASTROENTEROLOGY

Zip code

700-8558

Address

2-5-1 SHIKATA-CHO KITA-KU OKAYAMA CITY

TEL

086-235-7218

Homepage URL


Email

gyacy14@gmail.com


Sponsor or person

Institute

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Institute

Department

Personal name



Funding Source

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Address

2-5-1 SHIKATA-CHO KITA-KU OKAYAMA CITY

Tel

086-235-7218

Email

mae6605@adm.okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 09 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2013 Year 09 Month 03 Day

Date of IRB

2013 Year 08 Month 27 Day

Anticipated trial start date

2013 Year 09 Month 19 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

observe


Management information

Registered date

2013 Year 09 Month 19 Day

Last modified on

2021 Year 03 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013803


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name